Hospital
ST. Tammany Parish Hospital Service District No 1
ST. Tammany Parish Hospital Service District No 1 was paid $16.57M by Medicaid between Jan 2018 and Dec 2024, across 187 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoST. TAMMANY PARISH HOSPITAL SERVICE DISTRICT NO 1
COVINGTON, LA 70433
COVINGTON, LA 70433
33aNPI1598798597assigned 07/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.57M
24GClaims420,682
24DCodes billed187
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#25 of 96
Median peer was paid$5.17M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,423 | $1.37M | |
| 2019 | 46,147 | $1.68M | |
| 2020 | 30,640 | $1.20M | |
| 2021 | 61,478 | $2.66M | |
| 2022 | 90,775 | $3.77M | |
| 2023 | 91,100 | $3.47M | |
| 2024incomplete | 60,119 | $2.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 23,081 | 21,220 | $3.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 29,540 | 26,897 | $3.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 32,832 | 30,774 | $2.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.0% | 30,193 | 25,930 | $1.00M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 13,754 | 11,415 | $673K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.5% | 5,294 | 4,769 | $408K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 16,294 | 14,752 | $362K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.0% | 12,923 | 4,426 | $328K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.9% | 1,238 | 1,035 | $312K |
| 80053 | Comprehensive metabolic panel | 1.9% | 44,173 | 39,745 | $307K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.6% | 5,283 | 4,737 | $265K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 5,319 | 4,972 | $238K |
175 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 5,836 | $232K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 44,830 | $228K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 4,842 | $198K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 249 | $159K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,336 | $152K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,358 | $144K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,746 | $134K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,986 | $125K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 366 | $96K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,672 | $93K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,254 | $90K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,346 | $84K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 200 | $84K |
| 81025 | <1% | 14,103 | $80K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,507 | $80K |
| 42830 | <1% | 128 | $75K | |
| 25600 | <1% | 646 | $70K | |
| 20610 | <1% | 1,842 | $69K | |
| 73100 | <1% | 2,178 | $67K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,323 | $66K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,591 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 893 | $62K |
| 73610 | <1% | 1,931 | $59K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 376 | $57K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 950 | $57K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 138 | $56K |
| 84484 | <1% | 6,440 | $46K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,548 | $46K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,581 | $43K |
| 73630 | <1% | 1,172 | $42K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 300 | $41K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 634 | $40K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 999 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,857 | $37K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 708 | $37K |
| G0378 | Hospital observation service, per hour | <1% | 698 | $35K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 60 | $33K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,212 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 337 | $27K |
| 73564 | <1% | 518 | $26K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 74 | $26K |
| 73110 | <1% | 647 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,458 | $22K |
| 81001 | <1% | 9,639 | $21K | |
| 0240U | <1% | 232 | $21K | |
| 73030 | <1% | 682 | $21K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 805 | $17K |
| 73140 | <1% | 431 | $16K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 610 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,252 | $14K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 119 | $12K |
| 73080 | <1% | 373 | $11K | |
| 83880 | <1% | 525 | $11K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,496 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 292 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 120 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 170 | $10K |
| 99220 | <1% | 227 | $9K | |
| 80050 | General health panel | <1% | 233 | $9K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 149 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 203 | $8K |
| 59025 | Fetal non-stress test | <1% | 919 | $8K |
| 73521 | <1% | 189 | $8K | |
| 73130 | <1% | 220 | $8K | |
| 83735 | <1% | 1,754 | $7K | |
| 73560 | <1% | 320 | $7K | |
| 93017 | <1% | 104 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 149 | $7K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,490 | $6K |
| 81003 | <1% | 3,990 | $6K | |
| 87634 | <1% | 90 | $6K | |
| 93271 | <1% | 267 | $6K | |
| 80061 | Lipid panel | <1% | 703 | $5K |
| 83690 | <1% | 1,092 | $5K | |
| 27786 | <1% | 25 | $5K | |
| 77073 | <1% | 116 | $5K | |
| 73562 | <1% | 159 | $4K | |
| 73590 | <1% | 157 | $4K | |
| 94729 | <1% | 92 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 302 | $4K |
| 29085 | <1% | 124 | $4K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 145 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 63 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $3K |
| 93270 | <1% | 261 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 61 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $3K |
| 86003 | <1% | 159 | $3K | |
| 86803 | <1% | 183 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 76 | $3K |
| C1769 | Guide wire | <1% | 12 | $3K |
| 86703 | <1% | 225 | $3K | |
| 84439 | <1% | 219 | $2K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 260 | $2K |
| 94799 | <1% | 85 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,572 | $2K |
| 94010 | <1% | 58 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $2K |
| 94726 | <1% | 26 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,992 | $2K |
| 95806 | <1% | 31 | $1K | |
| 96376 | <1% | 49 | $1K | |
| 73090 | <1% | 51 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 169 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 255 | $1K |
| 84481 | <1% | 115 | $1K | |
| 72082 | <1% | 37 | $1K | |
| 90670 | <1% | 39 | $1K | |
| 94727 | <1% | 27 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,993 | $1K |
| 90686 | <1% | 349 | $955.31 | |
| 86850 | <1% | 388 | $931.52 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 12 | $857.53 |
| 87070 | <1% | 86 | $746.78 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 25 | $733.60 |
| 26720 | <1% | 12 | $728.41 | |
| 72170 | <1% | 28 | $710.25 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 12 | $668.00 |
| C1729 | Catheter, drainage | <1% | 13 | $662.72 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,698 | $642.59 |
| 99152 | <1% | 12 | $616.74 | |
| 99219 | <1% | 13 | $577.60 | |
| 0072A | <1% | 21 | $562.04 | |
| 82785 | <1% | 30 | $549.11 | |
| 85027 | <1% | 142 | $537.33 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 63 | $475.58 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 29 | $473.22 |
| 73000 | <1% | 12 | $446.28 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 153 | $435.22 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $427.57 |
| 86900 | <1% | 387 | $423.63 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 86 | $423.38 |
| 86901 | <1% | 384 | $419.33 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 45 | $379.34 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 783 | $373.00 |
| 0002A | <1% | 56 | $370.80 | |
| 82607 | <1% | 21 | $351.75 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $313.04 |
| 0225U | <1% | 15 | $312.59 | |
| 82746 | <1% | 19 | $310.46 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 106 | $284.16 |
| 82947 | <1% | 100 | $282.96 | |
| 72081 | <1% | 14 | $280.50 | |
| 82728 | <1% | 17 | $257.55 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 49 | $212.28 |
| 83550 | <1% | 18 | $174.78 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 593 | $174.68 |
| 80179 | <1% | 13 | $139.80 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,280 | $129.51 |
| 90647 | <1% | 24 | $128.52 | |
| 83540 | <1% | 18 | $114.12 | |
| 83605 | <1% | 22 | $92.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 29 | $69.80 |
| A4217 | Sterile water/saline, 500 ml | <1% | 275 | $67.88 |
| 82150 | <1% | 12 | $64.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 66 | $64.48 |
| 82550 | <1% | 26 | $22.81 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,863 | $17.01 |
| 99442 | <1% | 23 | $11.70 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,955 | $9.43 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 3,777 | $0.00 |
| 1111F | 0% | 90 | $0.00 | |
| 3008F | 0% | 117 | $0.00 | |
| 91307 | 0% | 14 | $0.00 | |
| 0001A | 0% | 16 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 24 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| J3490 | Unclassified drugs | 0% | 28 | $0.00 |
| 1160F | 0% | 367 | $0.00 | |
| 99490 | Ccm add 20min | 0% | 497 | $0.00 |
| 1159F | 0% | 370 | $0.00 | |
| 1124F | 0% | 14 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 36 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOFFMAN, JOAN (CEO/PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| ST. Tammany Parish Hospital Service District No 1 | Covington, LA | $1.56M |
| ST Tammany Parish Hospital Service District No 1 | Covington, LA | $770K |
| ST. Tammany Parish Hospital Service District No 1 | Madisonville, LA | $422K |
| ST. Tammany Parish Hospital Service District No 1 | Covington, LA | $412K |
| ST Tammany Parish Hospital Service District No 1 | Covington, LA | $142K |
| ST. Tammany Parish Hospital Service District No 1 | Folsom, LA | $123K |
| ST. Tammany Parish Hospital Service District No 1 | Covington, LA | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.